Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Phase Ib: Dose-limiting toxicities as measured by CTCAE v5.0
Timeframe: First day of treatment through completion of cycle 2 of therapy (each cycle is 28 days)
Pilot: Change in participants' concentration of circulating MDSCs with treatment
Timeframe: From pre- to post-treatment (end of post-op cycle 1; each cycle is 28 days).